The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Jul 8, 2026
· 7 min read
AI Analyzed
○ Unverifiable
View full audit trail →
Drug that could extend lives of Canadians with pancreatic cancer remains out of reach
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.278 · RIGHT
Ensemble
0.139 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.008
6,565 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Drug that could extend lives of Canadians with pancreatic cancer remains out of reach
KELLY GRANT
PUBLISHED 1 HOUR AGO
Open this photo in gallery:
Clinical trial results found that patients with previously treated metastatic pancreatic cancer survived a median of 13.2 months on new drug daraxonrasib, twice as long as 6.7 months on chemotherapy.
DANIELLE VILLASANA/REUTERS
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or create a free account to listen to this article.
When André Bourbeau learned last September that he had pancreatic cancer, he thought …
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
Jul 8, 2026